BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nicolò M, Ferro Desideri L, Vagge A, Traverso CE. Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs 2021;30:193-200. [PMID: 33471572 DOI: 10.1080/13543784.2021.1879791] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Lai TYY, Lai RYK. Association between Retinal Thickness Variability and Visual Acuity Outcome during Maintenance Therapy Using Intravitreal Anti-Vascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration. J Pers Med 2021;11:1024. [PMID: 34683165 DOI: 10.3390/jpm11101024] [Reference Citation Analysis]
2 Arrigo A, Bandello F. Molecular Features of Classic Retinal Drugs, Retinal Therapeutic Targets and Emerging Treatments. Pharmaceutics 2021;13:1102. [PMID: 34371793 DOI: 10.3390/pharmaceutics13071102] [Reference Citation Analysis]
3 Natale V, Stadlmayr G, Benedetti F, Stadlbauer K, Rüker F, Wozniak-Knopp G. Trispecific antibodies produced from mAb2 pairs by controlled Fab-arm exchange. Biol Chem 2022. [PMID: 35089662 DOI: 10.1515/hsz-2021-0376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kroenke MA, Milton MN, Kumar S, Bame E, White JT. Immunogenicity Risk Assessment for Multi-specific Therapeutics. AAPS J 2021;23:115. [PMID: 34741215 DOI: 10.1208/s12248-021-00642-5] [Reference Citation Analysis]
5 Bobadilla M, Pariente A, Oca AI, Peláez R, Pérez-sala Á, Larráyoz IM. Biomarkers as Predictive Factors of Anti-VEGF Response. Biomedicines 2022;10:1003. [DOI: 10.3390/biomedicines10051003] [Reference Citation Analysis]
6 Seyyar SA, Tokuc EO, Tıskaoğlu NS, Karabaş VL, Güngör K. Do serum vitamin D levels correlate with Macular Edema or with Diabetic Retinopathy? Eur J Ophthalmol 2022;:11206721221076701. [PMID: 35088606 DOI: 10.1177/11206721221076701] [Reference Citation Analysis]
7 Arrigo A, Aragona E, Bandello F. VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy. Ann Med 2022;54:1089-111. [PMID: 35451900 DOI: 10.1080/07853890.2022.2064541] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Ferro Desideri L, Traverso CE, Nicolò M. The emerging role of the angiopoietin-Tie pathway as therapeutic target for treating retinal diseases. Expert Opinion on Therapeutic Targets. [DOI: 10.1080/14728222.2022.2036121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Chatziralli I, Loewenstein A. Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature. Pharmaceutics 2021;13:1137. [PMID: 34452097 DOI: 10.3390/pharmaceutics13081137] [Reference Citation Analysis]
10 Zhang MY, Zhu L, Bao X, Xie TH, Cai J, Zou J, Wang W, Gu S, Li Y, Li HY, Yao Y, Wei TT. Inhibition of Drp1 ameliorates diabetic retinopathy by regulating mitochondrial homeostasis. Exp Eye Res 2022;:109095. [PMID: 35490835 DOI: 10.1016/j.exer.2022.109095] [Reference Citation Analysis]
11 Koistinen H, Künnapuu J, Jeltsch M. KLK3 in the Regulation of Angiogenesis-Tumorigenic or Not? Int J Mol Sci 2021;22:13545. [PMID: 34948344 DOI: 10.3390/ijms222413545] [Reference Citation Analysis]
12 Mundo L, Tosi GM, Lazzi S, Pertile G, Parolini B, Neri G, Posarelli M, De Benedetto E, Bacci T, Silvestri E, Siciliano MC, Barbera S, Orlandini M, Greenwood J, Moss SE, Galvagni F. LRG1 Expression Is Elevated in the Eyes of Patients with Neovascular Age-Related Macular Degeneration. Int J Mol Sci 2021;22:8879. [PMID: 34445590 DOI: 10.3390/ijms22168879] [Reference Citation Analysis]
13 Arrigo A, Bandello F. Retinal vein occlusion: drug targets and therapeutic implications. Expert Opin Ther Targets 2021;25:847-64. [PMID: 34775882 DOI: 10.1080/14728222.2021.2005026] [Reference Citation Analysis]
14 Surowka M, Schaefer W, Klein C. Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. MAbs 2021;13:1967714. [PMID: 34491877 DOI: 10.1080/19420862.2021.1967714] [Reference Citation Analysis]
15 Loukovaara S, Auvinen A, Haukka J. Associations between systemic medications and development of wet age-related macular degeneration. Acta Ophthalmol 2021. [PMID: 34779110 DOI: 10.1111/aos.15056] [Reference Citation Analysis]
16 Lokman Hakim NYDB, Noble S, Thomas NV, Geegana Gamage BS, Maxwell GK, Govindasamy V, Then KY, Das AK, Cheong SK. Genetic Modification as a New Approach to Ameliorate the Therapeutic Efficacy of Stem Cells in Diabetic Retinopathy. Eur J Ophthalmol 2022;:11206721211073430. [PMID: 35037488 DOI: 10.1177/11206721211073430] [Reference Citation Analysis]
17 Vagge A, Ferro Desideri L, Carnevali A, Del Noce C, Camposampiero D, Agrusta M, Ponzin D, Pellegrini M, Vaccaro S, Nicolò M, Scorcia V, Traverso CE, Giannaccare G. Efficacy of a New Commercial Ocular Spray Containing Oftasecur Citrus Extract for Reducing Microbial Load in the Conjunctiva of Patients Receiving Intravitreal Injections. Ophthalmol Ther 2021;10:1025-32. [PMID: 34495493 DOI: 10.1007/s40123-021-00384-9] [Reference Citation Analysis]
18 Le THV, Kwon SM. Vascular Endothelial Growth Factor Biology and Its Potential as a Therapeutic Target in Rheumatic Diseases. Int J Mol Sci 2021;22:5387. [PMID: 34065409 DOI: 10.3390/ijms22105387] [Reference Citation Analysis]
19 Rasoulinejad SA, Sarreshtehdari N, Mafi AR. The crosstalk between VEGF signaling pathway and long non-coding RNAs in neovascular retinal diseases: Implications for anti-VEGF therapy. Gene Reports 2022;27:101541. [DOI: 10.1016/j.genrep.2022.101541] [Reference Citation Analysis]